Wikidata

(Q63807803)

English

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

title
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (English)
0 references
start time
15 November 2016
0 references
end time
31 May 2026
0 references
number of participants
1,000
0 references
research site
University of Alabama
0 references
Loma Linda University
0 references
AdventHealth Porter
0 references
Swedish Medical Center
0 references
Danbury Hospital
0 references
Yale University
0 references
Norwalk Hospital
0 references
University of Miami
0 references
University of Chicago
0 references
York University
0 references
Mercy Medical Center
0 references
Boston University
0 references
University of Michigan
0 references
Hurley Medical Center
0 references
Munson Medical Center
0 references
Freeman Health System
0 references
UNM Los Lunas
0 references
Yeshiva University
0 references
Mount Sinai Hospital
0 references
Stony Brook University
0 references
Mission Health System
0 references
Wake Forest University
0 references
Cleveland Clinic
0 references
Ohio State University
0 references
University of Parma
0 references
Inova Health System
0 references
Huntington Hospital
0 references
Rutgers University
0 references
The Christ Hospital
0 references
Bryn Mawr Hospital
0 references
Vanderbilt University
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63807803&oldid=2233698060"